What is the J code for mitoxantrone?
What is the J code for mitoxantrone?
HCPCS Code J9293 J9293 is a valid 2021 HCPCS code for Injection, mitoxantrone hydrochloride, per 5 mg or just “Mitoxantrone hydrochl / 5 mg” for short, used in Medical care.
How is Prolia administered?
Denosumab injection comes as a solution (liquid) to be injected subcutaneously (under the skin) in your upper arm, upper thigh, or stomach area. It is usually injected by a doctor or nurse in a medical office or clinic. Denosumab injection (Prolia) is usually given once every 6 months.
What is the J code for Reclast?
HCPCS code J3489 (Injection, zoledronic acid 1 mg) should be used to report Reclast®. The number of units billed on a claim should be 5, since Relcast® is given as single 5 mg injection. Reclast is only administered once per 12 months, therefore, only one Reclast® claim should be submitted per year.
How do I bill J0897?
Use J0897, SC injection, denosumab, 1 mg. Use CPT code representing procedure performed, such as 96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular; or 96401, chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic.
What code is J0185?
J0185 is a valid 2021 HCPCS code for Injection, aprepitant, 1 mg or just “Inj., aprepitant, 1 mg” for short, used in Medical care.
What is the ICD 10 code for Prolia 60 mg?
Prolia® (denosumab) 60 mg HCPCS code (J-code): J0897 (injection, denosumab 1 mg)2 NDC number: 55513-0710-013 Use of a 60 mg prefilled syringe of Prolia® is reported as:
What is the HCPCS code for denosumab (Prolia™)?
Dose and frequency should be in accordance with the FDA label or recognized compendia (for off-label uses). When services are performed in excess of established parameters, they may be subject to review for medical necessity. HCPCS code J0897 should be used to report denosumab (Prolia™, Xgeva™) for claims submitted to the Part A and Part B MAC.
What are the brand names of Prolia and Xgeva?
The brand names and their indications are: * Prolia® – indicated to treat osteoporosis in women after menopause. * Xgeva® – indicated for the prevention of Skeletal-Related Events (SREs) in patients with bone metastases from solid tumors.
Is CPT® 96401 correct to report Prolia® administration?
My client had asked if CPT® 96401 Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic or CPT® 96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular is correct to report administration of Prolia®.
